Developing recombinant coronavirus vaccines for SARS

开发针对 SARS 的重组冠状病毒疫苗

• 批准号: 6818308
• 负责人: Xuming Zhang
• 金额: $ 51.77万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-07-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6818308
• 关键词: Coronaviridae; Macaca fascicularis; SDS polyacrylamide gel electrophoresis; cooperative study; cow; cytotoxic T lymphocyte; enzyme linked immunosorbent assay; flow cytometry; immune response; polymerase chain reaction; recombinant virus; severe acute respiratory syndrome; tissue /cell culture; vaccine development; vector vaccine; virus protein

DESCRIPTION (provided by applicant): The recent epidemic of the severe acute respiratory syndrome (SARS) is caused by a novel coronavirus, SARS-CoV. During the epidemic, more than 8,000 SARS cases and 812 deaths have been reported worldwide. With an ease of transmission and severity of the disease, SARS poses a great threat to public health and causes significant economic loss. It also presents a serious biodefense risk to the United States. To date, no effective anti-SARS drugs or vaccines are available. The long-term goal of this proposed research is to develop an efficacious vaccine for preventing future SARS epidemic. Current information obtained from studies on animal coronaviruses and their respective hosts suggests that the most promising vaccine for SARS would be a coronavirus-based live vaccine. However, the development of an attenuated, live SARS-CoV vaccine, though possible, is a long-term approach with an unpredictable outcome. Previously, the P.I. has isolated an enteric coronavirus from humans (termed HECoV), which is associated with acute, mild diarrhea but with no other severe clinical symptoms in children. Recent sequence analysis of the entire genome from our laboratory revealed that the HECoV isolate is most closely related to bovine coronavirus. Based on the tenet of a common mucosal immune system, antigenic stimulation by oral immunization is often very effective in inducing immunity to respiratory pathogens. Therefore, the P.I. proposes to develop a recombinant enteric HECoV expressing the antigenic proteins of the SARS-CoV as oral vaccines for SARS. Five aims are proposed: (1) to develop recombinant enteric HECoV expressing the ectodomain of the spike and other proteins of the SARS-CoV; (2) to characterize the biologic and genetic properties of the recombinant vaccines in cell culture; (3) to evaluate the safety and immunogenicity of the recombinant vaccines in germ-free calves; (4) to evaluate the safety, immunogenicity, and efficacy of the recombinant vaccines in non-human primates; (5) to develop a cell culture process for production of vaccines for human clinic trial (GMP).These studies will provide critical information for the development of an efficacious vaccine for SARS. The development of such a reverse genetic system will facilitate studies on molecular pathogenesis of coronaviruses and may provide potential avenues for development of vaccines for other severe infectious diseases such as AIDS.

描述（由申请人提供）：最近流行的严重急性呼吸系统综合症（SARS）是由一种新型冠状病毒SARS- cov引起的。在非典期间，全世界报告了8000多例SARS病例和812例死亡。由于其易传播性和严重程度，SARS对公众健康构成巨大威胁，并造成重大经济损失。它也给美国带来了严重的生物防御风险。到目前为止，还没有有效的抗sars药物或疫苗。这项拟议研究的长期目标是开发一种有效的疫苗，以预防未来的SARS流行。目前从动物冠状病毒及其各自宿主的研究中获得的信息表明，最有希望的SARS疫苗将是基于冠状病毒的活疫苗。然而，研制减毒sars冠状病毒活疫苗虽然是可能的，但这是一种长期方法，结果难以预测。此前，P.I.已经从人类中分离出一种肠道冠状病毒（称为HECoV），这种病毒与急性轻度腹泻有关，但在儿童中没有其他严重的临床症状。我们实验室最近对整个基因组的序列分析显示，HECoV分离物与牛冠状病毒最密切相关。基于共同粘膜免疫系统的原则，口服免疫的抗原刺激在诱导对呼吸道病原体的免疫方面通常是非常有效的。因此，P.I.建议开发一种表达SARS冠状病毒抗原蛋白的重组肠内HECoV作为SARS口服疫苗。提出了五个目标：(1)构建表达SARS-CoV刺突和其他蛋白外域的重组肠内HECoV；(2)在细胞培养中表征重组疫苗的生物学和遗传学特性；(3)评价重组疫苗在无菌犊牛体内的安全性和免疫原性；(4)评价重组疫苗在非人灵长类动物中的安全性、免疫原性和有效性；(5)开发用于生产人体临床试验疫苗的细胞培养工艺。这些研究将为研制有效的SARS疫苗提供关键信息。这种反向遗传系统的开发将促进对冠状病毒分子发病机制的研究，并可能为开发艾滋病等其他严重传染病的疫苗提供潜在途径。